MB

Mark Burrows

BCAL Diagnostics Limited | Non-Executive Director
Mr. Burrows is an advocate for early diagnosis of breast cancer and other cancers. He has enjoyed a career in investment banking in Australia and the UK. Mr. Burrows cofounded Baring Brothers Burrows & Co in Australia in the early 80s. In 1999 he was appointed the Managing Director / Deputy Chairman of ING Barings in London. In 2004, Mark joined Lazard as a Managing Partner and in 2006 returned to Australia and was appointed Lazard Australia's inaugural Chairman. Mr. Burrows returned to investment banking in 2011 as Vice Chairman of Credit Suisse's Global Investment Bank. During his investment banking career, Mr. Burrows has been the principal financial advisor to some of the corporate and government transactions in Australia. Mr. Burrows has served as a non-executive director on several Australasian and UK public companies including Chairman and Deputy Chair of Brambles, Fairfax Media and Telstra. Since the Rio Earth Summit in 1992, Mr. Burrows has also been an advocate of global financial institutions' Private Sector involvement in sustainable development. Over this period, Mr. Burrows has retained a number of roles advising United Nations, G20 and corporates on climate initiatives relating to the financial sector. From 2017 to 2020, Mr. Burrows was a Senior Advisor to Macquarie Bank, on climate finance and renewable energy. Mr Burrows currently retains a role as a senior advisor to UNEP, UNDP, The Green Finance Initiative in London and is on the Asian Council of The Nature Conservancy. He is also a Senior Advisor to the G20 Sustainability Group. Mr Burrows is a member of the Risk Management Committee.

Company and Role

Company
Title
Tenure
Since
BDX
BCAL Diagnostics Limited
  • Non-Executive Director
3yrs, 4mthJul 2021

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
BDX
BCAL Diagnostics Limited
30/08/241,450,000N/AN/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
BDX
BCAL Diagnostics Limited
24/11/23
Issued
300,000$0.100$30,000Placement
BDX
BCAL Diagnostics Limited
18/09/23
Buy
300,000$0.100$30,000Participation in share purchase plan
BDX
BCAL Diagnostics Limited
09/12/21
Buy
357,142$0.140$50,000On-market trade